Clinical and economic characteristics associated with type 2 diabetes;Características clínicas y económicas asociadas a la diabetes tipo 2

Revista Clinica Espanola

Volumn 214, Issue 3, 2014, Pages 121-130

  Sicras Mainar, A ^a   Navarro Artieda, R ^b   Ibanez Nolla J ^a  

^a Badalona Serveis Assistencials SA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cardiovascular disease; Diabetes; Health care costs; Hypoglycemia; Metabolic syndrome

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COMORBIDITY; COMPLICATION; FOLLOW UP; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; HYPERTENSION; HYPOGLYCEMIA; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PREVALENCE; RETROSPECTIVE STUDY; SPAIN; VERY ELDERLY; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; ECONOMICS; FEMALE; INCIDENCE; MALE; MIDDLE AGED; MULTICENTER STUDY; OVERWEIGHT; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; HYPERTENSION; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN;

EID: 84897579492     PISSN: 00142565     EISSN: 15781860     Source Type: Journal    
DOI: 10.1016/j.rce.2013.11.002     Document Type: Article

References (43)

1. A. Yazdanyar, and A.B. Newman The burden of cardiovascular disease in the elderly: Morbidity, mortality, and costs Clin Geriatr Med 25 2009 563 577
2. W.S. Weintraub, S.R. Daniels, L.E. Burke, B.A. Franklin, D.C. Goff Jr., L.L. Hayman American Heart Association Advocacy Coordinating Committee; Council on Cardiovascular Disease in the Young; Council on the Kidney in Cardiovascular Disease; Council on Epidemiology and Prevention; Council on Cardiovascular Nursing; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Clinical Cardiology, and Stroke Council. Value of primordial and primary prevention for cardiovascular disease: A policy statement from the American Heart Association Circulation 23 2011 967 990
3. S. Martin, W. Schramm, B. Schneider, K. Neeser, C. Weber, and V. Lodwig Epidemiology of complications and total treatment costs from diagnosis of Type 2 diabetes in Germany (ROSSO 4) Exp Clin Endocrinol Diabetes 115 2007 495 501
4. M.A. Martín Martínez, R. Carmona Alférez, F.J. Prado Galbarro, and A. Sarría Santamera Incidence and prevalence of diabetes in an adult population of Madrid (Spain): A study using computerized medical records in primary care Gac Sanit 27 2013 284 285
5. E. Gil Montalbán, B. Zorrilla Torras, H. Ortiz Marrón, M. Martínez Cortés, E. Donoso Navarro, and P. Nogales Aguado et al. Prevalence of diabetes mellitus and cardiovascular risk factors in the adult population of the autonomous region of Madrid (Spain): The PREDIMERC study Gac Sanit 24 2010 233 240
6. S. Sans, T. Padró, J. Tuomilehto, and L. Badimon Incidence of diabetes and serum adipokines in Catalonian men: The ADIPOCAT study Ann Med 45 2013 97 102
7. S. Valdés, G. Rojo-Martínez, and F. Soriguer Evolución de la prevalencia de la diabetes tipo 2 en población adulta española Med Clin (Barc) 129 2007 352 355
8. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, C.J. Paciorek Global Burden of Metabolic Risk Factors of Chronic Diseases Collaborating Group (Blood Glucose) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: Systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants Lancet 378 2011 31 40
9. A.S. Astrup Cardiovascular morbidity and mortality in diabetes mellitus: Prediction and prognosis Dan Med Bull 58 2011 B4152
10. M. Mata-Cases, P. Roura-Olmeda, M. Berengué-Iglesias, M. Birulés-Pons, X. Mundet-Tuduri, J. Franch-Nadal Diabetes Study Group in Primary Health Care (GEDAPS: Grup d'Estudi de la Diabetis a l'Atenció Primària de Salut, Catalonian Society of Family and Community Medicine). Fifteen years of continuous improvement of quality care of type 2 diabetes mellitus in primary care in Catalonia. Spain Int J Clin Pract 66 2012 289 298
11. K. Burgmann, S.A. Fatio, B. Jordi, and J. Rutishauser Medical care of type 2 diabetes mellitus in light of international and national recommendations: A retrospective analysis Swiss Med Wkly 143 2013 w13871
12. S.M. Joy, E. Little, N.M. Maruthur, T.S. Purnell, and J.F. Bridges Patient preferences for the treatment of type 2 diabetes: A scoping review Pharmacoeconomics 31 2013 877 892
13. American Diabetes Association Task Force for Writing Nutrition Principles and Recommendations for the Management of Diabetes and Related Complications American Diabetes Association position statement: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications J Am Diet Assoc 102 2002 109 118
14. E. Menéndez Torre, J. Lafita Tejedor, S. Artola Menéndez, J. Millán Núñez-Cortés, A. Alonso García, and M. Puig Domingo et al. Sociedad Española de Diabetes. Recommendations for the pharmacological treatment of hyperglycemia in type 2 diabetes Rev Clin Esp 211 2011 147 155
15. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD) Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379
16. L. Rydén, E. Standl, M. Bartnik, G. van den Berghe, J. Betteridge, M.J. de Boer Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: Executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur Heart J 28 2007 88 136
17. A. Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward The ADVANCE.collaborative group Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2008 2560 2572
18. D.M. Nathan, J.B. Buse, M.B. Davidson, E. Ferrannini, R.R. Colman, R. Sherwin American Diabetes Association; European Association for Study of Diabetes Medical Manegent of Hyperglycemia in Type 2 Diabetes: A Consensos Algorithm for the Initiation and Adjustment of Therapy. A consensus of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 2009 193 203
19. R.C. Turner, C.A. Cull, V. Frighi, R.R. Holman UK Prospective Diabetes Study (UKPDS) Group Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49) JAMA 281 1999 2005 2012
20. F.M. Ávila-Fematt, and M. Montaña-Álvarez Hypoglycemia in the elderly with diabetes mellitus Rev Invest Clin 62 2010 366 374
21. P. González, E. Faure, A. del Castillo Grupo de Trabajo para el Estudio del Coste de la Diabetes Cost of diabetes mellitus in Spain Med Clin (Barc) 127 2006 776 784
22. M. Mata, F. Antoñanzas, M. Tafalla, and P. Sanz El coste de la diabetes tipo 2 en España. El estudio CODE-2 Gac Sanit 16 2002 511 520
23. M.T. Vicente-Herrero, M.J. Terradillos García, L.M. Capdevila García, M.V. Ramírez Iñiguez de la Torre, and A.A. López-González Costs of temporary disability in Spain related to diabetes mellitus and its complications Endocrinol Nutr 60 2013 447 455
24. J. Stamler, O. Vaccaro, J.D. Neaton, and D. Wentworth Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
25. H. Lamberts, M. Wood, and Í.M. Hofmans-Okkes The Ínternational Classification of Primary Care in the European Community. With a multi-language layer. 1993 Oxford University Press Oxford
26. WHO; 1991. The Anatomical Therapeutic Chemical Classification System.
27. M.E. Charlson, P. Pompei, K.L. Ales, and C.R. Mackenzie A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation J Chronic Dis 40 1987 373 383
28. J.P. Weiner, B.H. Starfield, D.M. Steinwachs, and L.M. Mumford Development and application of a population-oriented measure of ambulatory care case-mix Med Care 29 1991 452 472
29. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment on High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Adult Treatment Panel III final report Circulation 106 2002 3143 3421
30. N. Sattar, A. Gaw, O. Scherbakova, I. Ford, D.S. O'Reilly, and S.M. Haffner et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study Circulation 108 2003 414 419
31. A. Sicras Mainar, C. Roldán Suárez, B. Font Ramos, R. Navarro Artieda, and J. Ibáñez Nolla Consecuencias clínicas y económicas de la combinación de metformina con inhibidores de la dipeptidilpeptidasa en pacientes con diabetes tipo 2 Rev Clin Esp 213 2013 377 384
32. S.G. Thompson, and J.A. Barber How should cost data in pragmatic randomised trials be analysed? BMJ 320 2000 1197 1200
33. N. Matikainen, and M.R. Taskinen Management of dyslipidemias in the presence of the metabolic syndrome or type 2 diabetes Curr Cardiol Rep 14 2012 721 731
34. R.B. Goldberg, and K. Mather Targeting the consequences of the metabolic syndrome in the Diabetes Prevention Program Arterioscler Thromb Vasc Biol 32 2012 2077 2090
35. C.C. Wang, and J.E. Reusch Diabetes and cardiovascular disease: Changing the focus from glycemic control to improving long-term survival Am J Cardiol 110 Suppl 9 2012 58B 68B
36. S.G. Coca, F. Ismail-Beigi, N. Haq, H.M. Krumholz, and C.R. Parikh Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: Systematic review and meta-analysis intensive glucose control in type 2 diabetes Arch Intern Med 172 2012 761 769
37. L. Breitscheidel, S. Stamenitis, F.W. Dippel, and O. Schöffski Economic impact of compliance to treatment with antidiabetes medication in type 2 diabetes mellitus: A review paper J Med Econ 13 2010 8 15
38. H. Wild The economic rationale for adherence in the treatment of type 2 diabetes mellitus Am J Manag Care 18 Suppl 3 2012 S43 S48
39. S. Shetty, K. Secnik, and A.K. Oglesby Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes J Manag Care Pharm 11 2005 559 564
40. T. Dilla, A. Valladares, C. Nicolay, J. Salvador, J. Reviriego, and M. Costi Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: The ECOBIM study Appl Health Econ Health Policy 10 2012 417 430
41. M. Ballesta, F. Carral Grupo de diabetes de la SAEN. Costes directos e indirectos de la diabetes mellitus tipo 2 Avances en Diabetes 18 Supl 1 2002 S20 S27
42. C.B. Giorda, V. Manicardi, and J. Diago Cabezudo The impact of diabetes mellitus on healthcare costs in Italy Expert Rev Pharmacoecon Outcomes Res 11 2011 709 719
43. J. Oliva, F. Lobo, B. Molina, and S. Monereo Estudio de los costes directos sanitarios de los pacientes con diabetes mellitus en España Diabetes Care 27 2004 2616 2621